

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Content Development Manager:** Pien van Spijker**Journal Manager:** Bharathi Sims**Publisher:** Fernanda Ogochi**Editorial Enquiries:***Drug Discovery Today*

Elsevier

125 London Wall, London, EC2Y 5AS, UK

Tel: +44 (0) 20 8439 5525

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Integrated Profiling, USA***David Cavalla** *Numedica Ltd., UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *ALN Associates, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Merck, USA***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, China***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *AstraZeneca, UK***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Acceleron Pharma Inc, USA***Mark Murcko** *Disruptive Biomedical, LLC, USA***Fajun Nan** *Shanghai Institute of Materia Medica, China***Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Clinical Semantics Group Consulting, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Microbiotix, Inc., USA***Manuel Peitsch** *Swiss Institute of Bioinformatics, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA***Janice Reichert** *Reichert Biotechnology Consulting LLC, MA, USA***John Reidhaar-Olson** *Albert Einstein College of Medicine, New York, USA***Mike Romanos** *Crescendo Biologics, Cambridge, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *EFS Strategy and Business Consulting, UK***Jonathan Sheldon** *Translational Medicine, Oracle, UK***Michael Snyder** *Stanford University, USA***Susie Stephens** *Johnson & Johnson, USA***Robert Strausberg** *Ludwig Institute for Cancer Research, New York, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Janssen Pharmaceutica, Belgium***Limsoon Wong** *National University of Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA***ScienceDirect**

DRUG DISCOVERY TODAY

POST SCREEN**2076 Drug repurposing: a promising tool to accelerate the drug discovery process***Vineela Parvathaneni, Nishant S. Kulkarni, Aaron Muth and Vivek Gupta***2086 Revisiting mTOR inhibitors as anticancer agents***Qiu-Xu Teng, Yunali V. Ashar, Pranav Gupta, Eddie. Gadee, Ying-Fang. Fan, Sandra E.Reznik, John N.D.Wurpel and Zhe-Sheng. Chen***2096 LMWH and its derivatives represent new rational for cancer therapy: construction strategies and combination therapy***Shi Du, Yao Yu, Cheng Xu, Hui Xiong, Shan Yang and Jing Yao***FORTHCOMING ARTICLES:****A human-on-a-chip approach to tackling rare diseases***By Camilly P. Pires de Mello, John Rumsey, Victoria Slaughter and James J. Hickman***Pharmacological Analysis of CFTR Variants of Cystic Fibrosis Using Stem-Cell Derived Organoids.***By Kevin G. Chen, Pingyu Zhong, Wei Zheng and Jeffrey M. Beekman***Novel insights into the role of urotensin II in cardiovascular disease***By João Pereira-Castro, Carmen Brás-Silva and Ana Patricia Fontes-Sousa***Early Access to Medicines Scheme: Real-World Data Collection.***By Hok Pang, Meng Wang, Christopher Kiff, Mira Soni, Dara Stein, and David Tyas.*